ACADIA Pharmaceuticals Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 81

ACADIA Pharmaceuticals Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “ACADIA Pharmaceuticals Inc. - Product Pipeline Review - H2 2011” provides data on the ACADIA Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ACADIA Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ACADIA Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ACADIA Pharmaceuticals Inc. - Brief ACADIA Pharmaceuticals Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ACADIA Pharmaceuticals Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ACADIA Pharmaceuticals Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ACADIA Pharmaceuticals Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ACADIA Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ACADIA Pharmaceuticals Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ACADIA Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ACADIA Pharmaceuticals Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ACADIA Pharmaceuticals Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of ACADIA Pharmaceuticals Inc.; ACADIA Pharmaceuticals Inc. - Key Therapeutics; ACADIA Pharmaceuticals Inc. - Pipeline Overview and Promising Molecules; ACADIA Pharmaceuticals Inc. - News; ACADIA Pharmaceuticals Inc. - Latest Updates; ACADIA Pharmaceuticals Inc. - Pipeline; ACADIA Pharmaceuticals Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
ACADIA Pharmaceuticals Inc. Snapshot
ACADIA Pharmaceuticals Inc. Overview
Key Information
Key Facts
ACADIA Pharmaceuticals Inc. – Research and Development Overview
Key Therapeutic Areas
ACADIA Pharmaceuticals Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
ACADIA Pharmaceuticals Inc. – Pipeline Products Glance
ACADIA Pharmaceuticals Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ACADIA Pharmaceuticals Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ACADIA Pharmaceuticals Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ACADIA Pharmaceuticals Inc. – Drug Profiles
AC 262271
Product Description
Mechanism of Action
R&D Progress
AC-260584
Product Description
Mechanism of Action
R&D Progress
ACP-105
Product Description
Mechanism of Action
R&D Progress
ACP-106
Product Description
Mechanism of Action
R&D Progress
AM-831
Product Description
Mechanism of Action
R&D Progress
Pimavanserin
Product Description
Mechanism of Action
R&D Progress
Pimavanserin + Risperidone
Product Description
Mechanism of Action
R&D Progress
ACADIA Pharmaceuticals Inc. – Pipeline Analysis
ACADIA Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class
ACADIA Pharmaceuticals Inc. - Pipeline Products By Target
ACADIA Pharmaceuticals Inc. – Pipeline Products by Route of Administration
ACADIA Pharmaceuticals Inc. – Pipeline Products by Molecule Type
ACADIA Pharmaceuticals Inc. – Recent Pipeline Updates
ACADIA Pharmaceuticals Inc. - Dormant Projects
ACADIA Pharmaceuticals Inc. – Company Statement
ACADIA Pharmaceuticals Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 29, 2010: ACADIA Initiates Phase III Trial With Pimavanserin For Parkinson's Disease Psychosis
Jun 29, 2007: ACADIA Pharmaceuticals Presents Favorable Results From Phase Ib/IIa Clinical Trial and PET Study of ACP-103 (Pimavanserin)
Mar 29, 2007: Acadia Pharmaceuticals' Schizophrenia Programs on Pimavanserin To Be Presented At The 2007 International Congress On Schizophrenia Research
Sep 26, 2002: ACADIA Discovers Novel Small Molecule Leads For The V2 Vasopressin Receptor
Jun 26, 2007: ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial With ACP-104
Apr 24, 2007: The USAN Approves Pimavanserin as Nonproprietary Name ACP-103
Mar 23, 2006: Acadia Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
Sep 22, 2005: ACADIA Pharmaceuticals Inc. Announces Publication Of Research In The Journal
Jun 22, 2004: ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103
Feb 21, 2006: ACADIA Pharmaceuticals Announces Advancements In Preclinical Programs ACP-105
Mar 19, 2007: Acadia Announces Positive Results From Pimavanserin (ACP-103) Phase II Schizophrenia Co-Therapy Trial
Jul 16, 2007: ACADIA Pharmaceuticals Earns Milestone On Advancement Of Glaucoma Drug Candidate
Jun 16, 2008: ACADIA Pharmaceuticals Announces Results From ACP-104 Phase IIb Schizophrenia Trial
Apr 16, 2008: ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting
Sep 15, 2004: Acadia Clinical Study Shows ACP-103 (pimavanserin)Improves Clinical Profile of Antipsychotic Drug Treatment
Apr 15, 2003: Allergan And ACADIA Pharmaceuticals Announce New Drug Discovery And Development Collaboration
Dec 14, 2007: ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting
Jul 13, 2006: ACADIA Pharmaceuticals Announces Encouraging Results From Initial Clinical Trials
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial With Pimavanserin In Patients With Parkinson's Disease Psychosis.
Dec 10, 2002: ACADIA Expands Pain Portfolio to Include New GPCR Targets
Nov 10, 2005: ACADIA Pharmaceuticals Inc. announced initial results from an ongoing clinical
Nov 09, 2010: ACADIA Pharmaceuticals Awarded Grant From The Michael J. Fox Foundation For The Development Of Novel Nurr1-RXR Agonists to Treat Parkinson's Disease.
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Sep 05, 2004: Acadia Pharmaceuticals Inc. Announces Publication Of Research Linking The Mechanism Of ACP-104
Apr 04, 2008: ACADIA Pharmaceuticals To Present Preclinical Data On ACP-105 And Its Muscarinic Discovery Program At Experimental Biology 2008 Meeting
Apr 04, 2008: ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104
Aug 03, 2004: ACADIA Pharmaceuticals Inc. Announces Publication Of Research Linking The Mechanism Of ACP-104
Apr 03, 2008: ACADIA Pharmaceuticals Initiates Second Phase III Trial With Pimavanserin In Patients With Parkinson's Disease Psychosis
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
Financial Deals Landscape
ACADIA Pharmaceuticals Inc., Deals Summary
ACADIA Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Abbey Pharmaceuticals Secures Seed Financing
Partnerships
ACADIA Pharmaceuticals Extends Drug Discovery Collaboration With Allergan
ACADIA Pharmaceuticals Expands Co-Development Agreement With Allergan
ACADIA Pharmaceuticals Enters Into Agreement With Meiji Seika Kaisha
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan
ACADIA Pharmaceuticals Enters Into An Agreement With Sepracor
ACADIA Pharmaceuticals Enters Into Co-Development Agreement With The Stanley Medical Research Institute
Licensing Agreements
Biovail Enters Into Licensing Agreement With ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Enters Into Licensing Agreement With Ipsen
ACADIA Pharmaceuticals Enters Into Licensing Agreement with Abbey Pharmaceuticals
Equity Offering
Acadia Pharmaceuticals Completes Private Placement Of $15 Million
ACADIA Pharmaceuticals Files Shelf Registration Statement For Public Offering Of $29 Million
ACADIA Pharmaceuticals Completes Public Offering Of $102 Million
ACADIA Pharmaceuticals Completes Public Offering Of $63 Million
ACADIA Pharmaceuticals Completes Private Placement Of $36 Million
ACADIA Pharmaceuticals Completes Initial Public Offering Of $35 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
ACADIA Pharmaceuticals Inc. – Pipeline by Therapy Area and Indication, H2 2011
ACADIA Pharmaceuticals Inc. – Pipeline by Stage of Development, H2 2011
ACADIA Pharmaceuticals Inc. – Monotherapy Products in Pipeline, H2 2011
ACADIA Pharmaceuticals Inc. – Combination Treatment Modalities in Pipeline, H2 2011
ACADIA Pharmaceuticals Inc. – Phase III, H2 2011
ACADIA Pharmaceuticals Inc. - Phase II, H2 2011
ACADIA Pharmaceuticals Inc. - Phase I, H2 2011
ACADIA Pharmaceuticals Inc. - Pipeline By Therapeutic Class, H2 2011
ACADIA Pharmaceuticals Inc. - Pipeline By Target, H2 2011
ACADIA Pharmaceuticals Inc. – Pipeline By Route of Administration, H2 2011
ACADIA Pharmaceuticals Inc. – Pipeline By Molecule Type, H2 2011
ACADIA Pharmaceuticals Inc. – Recent Pipeline Updates, H2 2011
ACADIA Pharmaceuticals Inc. - Dormant Developmental Projects, 2010
ACADIA Pharmaceuticals Inc., Subsidiaries
ACADIA Pharmaceuticals Inc., Deals Summary
Abbey Pharmaceuticals Secures Seed Financing
ACADIA Pharmaceuticals Extends Drug Discovery Collaboration With Allergan
ACADIA Pharmaceuticals Expands Co-Development Agreement With Allergan
ACADIA Pharmaceuticals Enters Into Agreement With Meiji Seika Kaisha
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan
ACADIA Pharmaceuticals Enters Into An Agreement With Sepracor
ACADIA Pharmaceuticals Enters Into Co-Development Agreement With The Stanley Medical Research Institute
Biovail Enters Into Licensing Agreement With ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Enters Into Licensing Agreement With Ipsen
ACADIA Pharmaceuticals Enters Into Licensing Agreement with Abbey Pharmaceuticals
Acadia Pharmaceuticals Completes Private Placement Of $15 Million
ACADIA Pharmaceuticals Files Shelf Registration Statement For Public Offering Of $29 Million
ACADIA Pharmaceuticals Completes Public Offering Of $102 Million
ACADIA Pharmaceuticals Completes Public Offering Of $63 Million
ACADIA Pharmaceuticals Completes Private Placement Of $36 Million
ACADIA Pharmaceuticals Completes Initial Public Offering Of $35 Million

List of Figures
ACADIA Pharmaceuticals Inc. – Pipeline by Therapy Area and Indication, H2 2011
ACADIA Pharmaceuticals Inc. – Pipeline by Stage of Development, H2 2011
ACADIA Pharmaceuticals Inc. – Monotherapy Products in Pipeline, H2 2011
ACADIA Pharmaceuticals Inc. – Combination Treatment Modalities in Pipeline, H2 2011
ACADIA Pharmaceuticals Inc. – Pipeline By Therapeutic Class, H2 2011
ACADIA Pharmaceuticals Inc. - Pipeline By Target, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Analysis of Google Inc
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Abbott Laboratories - IT Sales Opportunities - 2009